We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+58.74%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$447M
AUM Growth
+$69.6M
Cap. Flow
-$23.8M
Cap. Flow %
-5.33%
Top 10 Hldgs %
68.5%
Holding
29
New
4
Increased
4
Reduced
6
Closed
3

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$15.3M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$11.8M
3
SLN
Silence Therapeutics
SLN
+$10.4M
4
ADVM
Adverum Biotechnologies
ADVM
+$8.24M
5
TYRA icon
Tyra Biosciences
TYRA
+$6.3M

Top Sells

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$20.3M
2
IRON icon
Disc Medicine
IRON
+$17M
3
VKTX icon
Viking Therapeutics
VKTX
+$15.5M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.3M
5
SPRB
Spruce Biosciences
SPRB
+$6.93M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
26
DELISTED
Cidara Therapeutics
CDTX
$1.04M 0.23%
56,726
– –
IRON icon
27
Disc Medicine
IRON
$2.99B
– –
-294,221
Closed -$17M
SPRB
28
Spruce Biosciences
SPRB
$127M
– –
-31,520
Closed -$6.93M
MRTX
29
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-192,500
Closed -$11.3M
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q1 2024 Portfolio in Review

As of Q1 2024, 5AM Venture Management held 29 positions worth $447M, up 18% from $377M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

5AM Venture Management withdrew a net $23.8M in Q1 2024, closing 3 positions and reducing 6 holdings. Its most notable exit was Disc Medicine, an estimated $17M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, 5AM Venture Management opened a new position in Praxis Precision Medicines worth $20.7M.

  • 5AM Venture Management's largest Q1 2024 buy was Praxis Precision Medicines: 340,000 shares worth $20.7M.
  • 5AM Venture Management added most to Tyra Biosciences in Q1 2024, an estimated $6.3M increase.
  • 5AM Venture Management's biggest Q1 2024 reduction was Enliven Therapeutics, cutting an estimated $20.3M.
  • 5AM Venture Management fully exited Disc Medicine in Q1 2024, selling an estimated $17M.
  • 5AM Venture Management's ten largest holdings make up 68% of its $447M portfolio in Q1 2024.
  • 5AM Venture Management opened 4 new positions and closed 3 in Q1 2024.
  • 5AM Venture Management's portfolio value rose 18% quarter-over-quarter to $447M.

Based on 5AM Venture Management's 13F filing for Q1 2024, filed 15 May 2024.